David Moatazedi Evolus, Inc. (EOLS) insider trading activity

David Moatazedi is Director of Evolus, Inc.. Currently has a direct ownership of 364,927 shares of EOLS, which is worth approximately $3.34 Million. The most recent transaction as insider was on Jun 16, 2025, when has been sold 16,582 shares (Common Stock) at a price of $9.89 per share, resulting in proceeds of $163,995. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 365K

28.25% 3M change

31.58% 12M change

Total Value Held $3.34 Million

DAVID MOATAZEDI Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 16 2025	SELL Open market or private sale	$163,995 $9.89 p/Share	16,582 Reduced 4.35%	364,927 Common Stock
Jun 13 2025	SELL Open market or private sale	$1,118,796 $10.05 p/Share	111,323 Reduced 22.59%	381,509 Common Stock
May 12 2025	SELL Open market or private sale	$155,817 $9.87 p/Share	15,787 Reduced 3.1%	492,832 Common Stock
Mar 27 2025	SELL Open market or private sale	$77,512 $12.4 p/Share	6,251 Reduced 1.21%	508,619 Common Stock
Mar 18 2025	SELL Open market or private sale	$1,370,765 $13.26 p/Share	103,376 Reduced 16.72%	514,870 Common Stock
Mar 07 2025	BUY Grant, award, or other acquisition	-	95,399 Added 13.37%	618,246 Common Stock
Dec 23 2024	SELL Open market or private sale	$113,946 $10.85 p/Share	10,502 Reduced 1.97%	522,847 Common Stock
Jun 06 2024	SELL Open market or private sale	$2,215,084 $12.59 p/Share	175,940 Reduced 24.81%	533,349 Common Stock
Jun 06 2024	BUY Exercise of conversion of derivative security	$1,280,843 $7.28 p/Share	175,940 Added 19.88%	709,289 Common Stock
Jun 05 2024	SELL Open market or private sale	$2,006,191 $12.92 p/Share	155,278 Reduced 22.55%	533,349 Common Stock
Jun 05 2024	BUY Exercise of conversion of derivative security	$847,817 $5.46 p/Share	155,278 Added 18.4%	688,627 Common Stock
Jun 04 2024	SELL Open market or private sale	$1,784,924 $12.73 p/Share	140,214 Reduced 20.82%	533,349 Common Stock
May 10 2024	SELL Open market or private sale	$204,168 $12.72 p/Share	16,051 Reduced 2.33%	673,563 Common Stock
Mar 27 2024	SELL Open market or private sale	$86,430 $13.86 p/Share	6,236 Reduced 0.9%	689,614 Common Stock
Mar 19 2024	SELL Open market or private sale	$1,344,198 $13.92 p/Share	96,566 Reduced 12.19%	695,850 Common Stock
Feb 22 2024	SELL Open market or private sale	$100,794 $13.08 p/Share	7,706 Reduced 0.96%	792,416 Common Stock
Feb 21 2024	BUY Grant, award, or other acquisition	-	61,202 Added 7.11%	800,122 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	134,976 Added 15.45%	738,920 Common Stock
Dec 08 2023	SELL Open market or private sale	$304,549 $9.73 p/Share	31,300 Reduced 4.93%	603,944 Common Stock
Dec 06 2023	SELL Open market or private sale	$518,101 $10.09 p/Share	51,348 Reduced 7.48%	635,244 Common Stock
Aug 16 2023	SELL Open market or private sale	$151,770 $10.27 p/Share	14,778 Reduced 2.11%	686,592 Common Stock
Aug 14 2023	BUY Grant, award, or other acquisition	-	91,803 Added 11.57%	701,370 Common Stock
Mar 27 2023	SELL Open market or private sale	$51,751 $8.47 p/Share	6,110 Reduced 0.99%	609,567 Common Stock
Mar 14 2023	SELL Open market or private sale	$543,867 $8.47 p/Share	64,211 Reduced 9.44%	615,677 Common Stock
Jan 25 2023	BUY Grant, award, or other acquisition	-	187,927 Added 21.66%	679,888 Common Stock

Also insider at

BMRA

BIOMERICA INC Healthcare

Director

David Moatazedi

Director

Newport Beach, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EOLS shares.

Notify only if

Value

Insider Trading

Get notified when an Evolus, Inc. insider buys or sells EOLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Evolus, Inc.

Track Activities on EOLS

Account